Most of the new wave of drugs in
development act to
block the actions of specific proteins that bring on symptoms of
diabetes, or they work to reduce obesity by dissolving fat or controlling appetite.
The finding, published in the journal Developmental Cell, opens up new possibilities for the
development of drugs that
block MCRS1 to treat cancer and
diabetes.